Picici direct Research

CMP: ₹ 3762

Target: ₹ 4200 (12%)

Target Period: 12 months

HOLD

January 21, 2021

Volume continues to remain sluggish

VST Industries reported dismal set of numbers with ~13% decline in cigarette volumes given demand conditions still remained weak due to continue work from home culture. Moreover, the company faced stiff competitive pressure with peers increasing trade discounts & schemes. Gross revenues witnessed a growth of 3.3% led by 18% increase in cigarettes sales. The increase in sales was largely on account of price increase taken last year after the excise duty increase in budget & change in product mix. High priced cigarettes brands 'Total' (₹ 7/stick) & 'Edition' (₹11/stick) contributes 45% to volumes. Tobacco sales was down to ₹ 60 crore from ₹ 100 crore in corresponding quarter due to sluggish demand of Indian tobacco in export market. The company paid ₹ 93.5 crore excise duty as against ₹ 24.7 crore in corresponding quarter. Gross margins were higher by 674 bps mainly due to increase in cigarettes prices & change in product mix towards the high priced cigarettes. Operating profit dipped by 7.8% to ₹ 100 crore. Net profit witnessed de-growth of 9.5% to ₹ 73.7 crore.

Stability in taxation is key to growth

Cigarette Industry faced stiff challenges of excise duty increase & pandemic induced lockdown in FY21. This resulted in significant declined in cigarettes volumes for the Industry. In similar lines, VST also witnessed 22% cigarette volume decline in 9MFY21. Work from home culture & still some restrictions on large celebratory gatherings has been one of the major reasons for continued volume de-growth. We believe stable taxation is key for recouping lost volumes in next two years. We have seen two years of stable taxation between FY18-20 resulted in double digit growth in cigarettes volumes. We expect 2.6% revenue CAGR during FY20-23 with 6% & 3% volume growth in FY22E & FY23E. Considering continuous increasing contribution of premium priced cigarettes, we expect operating margin improvement & subsequent earnings CAGR of 6.1% in FY20-23E.

Strong free cash flows; high dividend pay-out

VST is generating ~₹ 300 crore (on an average) free cash flow every year from FY18 onwards. Despite, severe impact on volumes, it has been able to maintain similar profitability & continuation of strong free cash flows in FY21E. Moreover, it has consistently paid ~65% dividend in last five years (except 52% in current year due to uncertainty over pandemic). We believe pay-out would increase to 70% given company is holding more than ₹700 crore of cash & equivalent & doesn't have any capex requirement in future. Despite, expected subdued earning, we expect RoCE & RoE to improve to 52.8% & 39% respectively by FY23E

Valuation & Outlook

The company has maintained its profitability despite severe volume challenges shows its ability to manoeuvre pricing & promotion to its advantage. However, we believe stable taxation is necessary for volume growth in future, which would determine revenue & earnings trajectory for the next few years. We will wait for cues in 2021 budget and maintain our **Hold** with revised target price of ₹ 4200/share (18x FY23E PE)



VST Industries Ltd.

| Particulars | |
|-----------------------------|-------------|
| Particulars (₹ crore) | Amount |
| Market Capitalization | 5,809.2 |
| Total Debt (FY19) | 0.0 |
| Cash and Investments (FY20) | 788.6 |
| EV | 5,020.6 |
| 52 week H/L (₹) | 4856 / 3010 |
| Equity capital | ₹ 15.4 |
| Face value (₹) | 10.0 |

Price Chart



Key Risk to our call

- **Downside Risk** : Any significant change in taxation in 2021 Budget or any of the GST council meeting
- Upside Risk : Volume recovery in FY22E could be much faster than our estimate of 6%

Research Analyst

Sanjay Manyal sanjay.manyal@icicisecurities.com

| Key Financial Summary | | | | | | |
|-----------------------|--------|--------|--------|--------|--------|-----------------|
| Key Financials | FY19 | FY20 | FY21E | FY22E | FY23E | CAGR (FY20-23E) |
| Net Sales | 1097.6 | 1238.1 | 1150.1 | 1237.8 | 1336.3 | 2.6% |
| EBITDA | 353.1 | 414.7 | 414.1 | 446.5 | 486.4 | 5.5% |
| EBITDA Margin % | 32.2 | 33.5 | 36.0 | 36.1 | 36.4 | |
| Net Profit | 226.8 | 304.1 | 312.5 | 337.7 | 363.2 | 6.1% |
| EPS (₹) | 146.90 | 196.95 | 202.40 | 218.70 | 235.24 | |
| P/E | 25.6 | 19.1 | 18.6 | 17.2 | 16.0 | |
| RoNW % | 34.2 | 38.6 | 33.2 | 35.2 | 39.0 | |
| RoCE (%) | 51.4 | 52.1 | 44.7 | 47.4 | 52.8 | |

ICICI Securities – Retail Equity Research

Result Update

Source: Company, ICICI Direct Research

| | Q3FY21 | Q3FY21E | Q3FY20 | YoY (%) | Q2FY21 | QoQ (%) | Comments |
|----------------------------|--------|----------------|--------|---------|--------|----------|--|
| | | | | | | (1 | Gross revenue increased by 3.3% however, net of excise sales |
| Total Operating Income | 286.9 | 306.3 | 343.8 | -16.5 | 300.3 | -4.5 | saw 16.5% decline in sales largely on account of 40% dip in |
| 1 5 | | | | | | | tobacco sales & 13% decline in cigarettes volumes |
| Other Operating Income | 0.3 | 0.5 | 0.6 | -46.9 | 0.3 | 3.0 | |
| Raw Material Expenses | 129.4 | 131.1 | 178.2 | -27.4 | 135.0 | -4.2 | Gross margins improved significantly due to price hikes taken last |
| naw waterial expenses | 129.4 | 131.1 | 1/0.2 | -27.4 | 135.0 | -4.Z | year after budget & chane in product mix |
| Employee Expense | 29.4 | 28.0 | 30.5 | -3.6 | 28.1 | 4.6 | |
| Excise Duty | 93.5 | 100.2 | 24.7 | 278.5 | 94.6 | -1.1 | |
| Other operating Expenses | 28.2 | 31.5 | 26.7 | 5.4 | 24.1 | 16.8 | |
| EBITDA | 100.0 | 115.7 | 108.4 | -7.8 | 113.1 | -11.6 | |
| | | | | | | | Operating margins improved on the back of expansion in gross |
| EBITDA Margin (%) | 34.8 | 37.8 | 31.5 | 332 bps | 37.6 | -280 bps | margins partially off-set of higher fixed cost due to negative |
| | | | | | | | operating leverage |
| Depreciation | 9.4 | 10.9 | 10.3 | -8.4 | 8.9 | 5.4 | |
| Interest | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | |
| Other Income | 9.2 | 10.8 | 11.1 | -17.0 | 14.7 | -37.5 | |
| | 00.7 | 115.0 | 100.0 | 0.0 | 110.0 | 10.1 | |
| PBT | 99.7 | 115.6 | 109.2 | -8.6 | 118.8 | -16.1 | |
| Tax Outgo | 26.0 | 27.6 | 27.7 | -6.0 | 30.3 | -14.1 | |
| PAT | 73.7 | 88.0 | 81.5 | -9.5 | 88.5 | -16.7 | Net profit saw 9.5% de-growth during the quarter |
| Key Metrics | | | | | | | |
| 0; // 0 / T) | | 010.0 | 007.0 | 10 5 | 000.0 | 4.0 | Cigarette sales was higher despite significant dip in volumes |
| Cigarette Sales (₹ crore) | 220.1 | 316.0 | 267.8 | 19.5 | 333.6 | -4.0 | mainly due to increase in cigarette prices last year & change in |
| | 320.1 | | | | | | product mix |
| Tobacco Sales (₹ crore) | 60.0 | 90.0 | 100.0 | -40.0 | 61.0 | -1.6 | Tobacco sales was lower mainly on account of lower export demand for Indian tobacco |

Source: Company, ICICI Direct Research

| | | FY21E | | | FY22E | FY22E FY2 | | | | Comments |
|-------------------|--------|--------|----------|---------|---------|-----------|---------|---------|----------|---|
| (₹ Crore) | Old | New | % change | Old | New | % change | Old | New | % change | |
| Net sales | 1169.1 | 1150.1 | -1.6 | 1,258.2 | 1,237.8 | -1.6 | 1,358.1 | 1,336.3 | -1.6 | We marginally change our estimate of realisation growth given trade discounts are back of pre-covid |
| EBITDA | 421.6 | 414.1 | -1.8 | 432.4 | 446.5 | 3.3 | 462.6 | 486.4 | 5.1 | |
| EBITDA Margin (%) | 36.1 | 36.0 | -6 bps | 34.4 | 36.1 | 171 bps | 34.1 | 36.3 | 228 bps | We changed our gross margin estimate for FY22 & FY23 with company pushing for higher proportion premium priced cigarettes |
| PAT | 318.1 | 312.5 | -1.8 | 327.2 | 337.7 | 3.2 | 345.7 | 363.2 | 5.1 | |
| EPS (₹) | 206.0 | 202.40 | -1.8 | 211.9 | 218.70 | 3.2 | 223.9 | 235.2 | 5.1 | |

Source: Company, ICICI Direct Research

| | | | | | | | Earlier | | Comments |
|------------------------|---------|---------|---------|---------|---------|---------|---------|---------|---|
| | FY19 | FY20 | FY21E | FY22E | FY23E | FY21E | FY22E | FY23E | |
| Cig. Vol. (mn sticks) | 8,031.1 | 8,753.9 | 7,353.3 | 7,794.5 | 8,028.3 | 7,353.3 | 7,794.5 | 8,028.3 | No major change in estimates |
| Cig. Vol. Growth (%) | 9.0 | 9.0 | -16.0 | 6.0 | 3.0 | -16.0 | 6.0 | 3.0 | |
| Realization/cig (₹) | 1.2 | 1.3 | 1.7 | 1.7 | 1.8 | 1.7 | 1.8 | 1.8 | Small change in realisation growth estimate as trade promotions are back to pre-covid levels |
| Tobacco Sales(₹ crore) | 238.9 | 264.7 | 251.5 | 271.9 | 285.6 | 251.5 | 271.9 | 285.6 | |
| % of <64mm in sales | 40.0 | 40.0 | 40.0 | 40.0 | 40.0 | 40.0 | 40.0 | 40.0 | |
| % of >64mm in sales | 60.0 | 60.0 | 60.0 | 60.0 | 60.0 | 60.0 | 60.0 | 60.0 | |

Source: Company, ICICI Direct Research

Key Metrics




Exhibit 5: Steeper than expected volume decline in FY23E 40.0 33.0 30.0 15.1 20.0 9.07.0 9.0 1.2^{4.5} 6.01.0 10.0 3.04.0 2.0 0.0 -0.7 -10.0 -20.0 16.0 FY21E FY22E FY17 FY18 FY19 FY20 FY23E

Realisation growth (%)


Source: ICICI Direct Research, Company

Exhibit 6: Improved product mix to aid EBITDA margins



Source: ICICI Direct Research, Company

Volume Growth (%)



Source: Company, ICICI Direct Research


Source: Company, ICICI Direct Research

Exhibit 9: Attractive Return ratios % (except bump in FY21)

52.1

34.2

FY20



Source: Company, ICICI Direct Research

Source: Company, ICICI Direct Research

180.0

160.0

140.0 ·

120.0

100.0

80.0 -

60.0

40.0

20.0

0.0

| | Sales | Growth | EPS | Growth | PE | EV/EBITDA | RoNW | RoCE |
|-------|--------|--------|-------|--------|------|-----------|------|------|
| | (₹ cr) | (%) | (₹) | (%) | (x) | (x) | (%) | (%) |
| FY20 | 1238.1 | 12.8 | 196.9 | 34.1 | 19.1 | 13.9 | 38.6 | 52.1 |
| FY21E | 1150.1 | -7.1 | 202.4 | 2.8 | 18.6 | 13.5 | 33.2 | 44.7 |
| FY22E | 1237.8 | 7.6 | 218.7 | 8.1 | 17.2 | 12.8 | 35.2 | 47.4 |
| FY23E | 1336.3 | 8.0 | 235.2 | 7.6 | 16.0 | 11.8 | 39.0 | 52.8 |

Source: Company, ICICI Direct Research

52.8

35.2

FY23E

47.4

33.2

FY22E

44.7

38.6

FY21E

RoNW(%)

Financial summary

| Exhibit 11: Profit and lose | s statemen | t | | ₹ crore |
|-----------------------------|------------|--------|--------|---------|
| (Year-end March) | FY20 | FY21E | FY22E | FY23E |
| Total Operating Income | 1239.4 | 1151.7 | 1239.7 | 1338.5 |
| Growth (%) | 12.8 | -7.1 | 7.6 | 8.0 |
| Raw Material Expenses | 598.6 | 513.3 | 560.4 | 594.2 |
| Employee Expenses | 102.4 | 115.0 | 117.6 | 131.0 |
| Excise Duty | 131.1 | 364.2 | 386.0 | 397.6 |
| Administrative Expenses | 0.0 | 0.0 | 0.0 | 0.0 |
| Other expenses | 123.7 | 109.3 | 115.1 | 126.9 |
| Total Operating Expenditure | 824.7 | 737.6 | 793.1 | 852.1 |
| EBITDA | 414.7 | 414.1 | 446.5 | 486.4 |
| Growth (%) | 17.4 | -0.1 | 7.8 | 8.9 |
| Depreciation | 41.8 | 39.6 | 39.0 | 42.0 |
| Interest | 0.0 | 0.0 | 0.0 | 0.0 |
| Other Income | 0.0 | 0.0 | 0.0 | 0.0 |
| PBT | 420.3 | 422.3 | 456.3 | 494.2 |
| Others | 47.4 | 47.8 | 48.8 | 49.8 |
| Total Tax | 116.2 | 109.8 | 118.6 | 131.0 |
| PAT | 304.1 | 312.5 | 337.7 | 363.2 |
| Growth (%) | 34.1 | 2.8 | 8.1 | 7.6 |
| EPS (₹) | 196.9 | 202.4 | 218.7 | 235.2 |

| Exhibit 12: Cash flow statem | nent | | | ₹ crore |
|--------------------------------|--------|--------|--------|---------|
| (Year-end March) | FY20 | FY21E | FY22E | FY23E |
| Profit after Tax | 314.8 | 312.5 | 337.7 | 363.2 |
| Add: Depreciation | 41.8 | 39.6 | 39.0 | 42.0 |
| (Inc)/dec in Current Assets | -29.0 | 71.9 | -152.7 | -60.8 |
| Inc/(dec) in CL and Provisions | 49.6 | -73.3 | 32.6 | 43.7 |
| CF from operating activities | 331.4 | 350.7 | 256.6 | 388.1 |
| (Inc)/dec in Investments | -133.3 | 0.2 | -0.1 | -0.1 |
| (Inc)/dec in Fixed Assets | -21.9 | -40.0 | -35.0 | -35.0 |
| (Inc)/dec in LT Loans & Adv. | 0.0 | 0.0 | 0.0 | 0.0 |
| Others | 0.5 | -16.4 | 0.3 | 0.3 |
| CF from investing activities | -154.8 | -56.2 | -34.9 | -34.8 |
| Issue/(Buy back) of Equity | 0.0 | 0.0 | 0.0 | 0.0 |
| Inc/(dec) in loan funds | 0.0 | 0.0 | 0.0 | 0.0 |
| Dividend paid & dividend tax | -176.9 | -159.0 | -319.7 | -390.4 |
| Inc/(dec) in Reval. Reserve | 0.0 | 0.0 | 0.0 | 0.0 |
| Inc/(dec) in Exch. Fluc. Res. | 0.0 | 0.0 | 0.0 | 0.0 |
| CF from financing activities | -176.9 | -159.0 | -319.7 | -390.4 |
| Net Cash flow | -0.2 | 135.5 | -97.9 | -37.1 |
| Opening Cash | 26.4 | 26.2 | 161.7 | 63.7 |
| Closing Cash | 37.4 | 172.9 | 75.0 | 37.8 |

Source: Company, ICICI Direct Research

(Year-end March)

Per share data (₹)

Exhibit 14: Key ratios

Source: Company, ICICI Direct Research

| Exhibit 13: Balance sheet | | | | ₹ crore | | |
|----------------------------|-------|-------|-------|---------|--|--|
| (Year-end March) | FY20 | FY21E | FY22E | FY23E | | |
| Liabilities | | | | | | |
| Equity Capital | 15.4 | 15.4 | 15.4 | 15.4 | | |
| Reserve and Surplus | 771.7 | 925.1 | 943.1 | 915.9 | | |
| Total Shareholders funds | 787.1 | 940.6 | 958.5 | 931.3 | | |
| Total Debt | 0.0 | 0.0 | 0.0 | 0.0 | | |
| Long Term Provisions | 19.9 | 3.5 | 3.7 | 4.0 | | |
| Total Liabilities | 806.9 | 944.0 | 962.2 | 935.3 | | |
| Assets | | | | | | |
| Gross Block | 345.0 | 375.0 | 405.0 | 435.0 | | |
| Less: Acc Depreciation | 157.9 | 197.5 | 236.5 | 278.5 | | |
| Net Block | 187.1 | 177.5 | 168.5 | 156.5 | | |
| Capital WIP | 12.7 | 22.7 | 27.7 | 32.7 | | |
| Deferred Tax Asset | 26.4 | 26.4 | 26.4 | 26.4 | | |
| Non Current Investments | 1.8 | 1.6 | 1.7 | 1.8 | | |
| LT Loans & Advances/Others | 5.4 | 5.4 | 5.4 | 5.4 | | |
| Current Assets | | | | | | |
| Inventory | 297.7 | 274.1 | 298.4 | 322.2 | | |
| Debtors | 15.4 | 14.2 | 17.0 | 18.3 | | |
| Cash | 37.4 | 172.9 | 75.0 | 37.8 | | |
| Loans & Advances | 0.0 | 7.9 | 8.5 | 9.2 | | |
| Current Investments | 751.2 | 691.2 | 811.2 | 841.2 | | |
| Other CA | 62.0 | 67.0 | 72.0 | 77.0 | | |
| Current Liabilities | | | | | | |
| Creditors | 142.8 | 138.6 | 142.4 | 153.8 | | |
| Provisions | 0.0 | 0.0 | 0.0 | 0.0 | | |
| Other CL | 447.3 | 378.1 | 407.0 | 439.3 | | |
| Net Current Assets | 573.6 | 710.5 | 732.6 | 712.6 | | |
| Total Assets | 806.9 | 944.0 | 962.2 | 935.3 | | |

EPS 196.9 202.4 218.7 235.2 Cash EPS 224.0 228.0 244.0 262.4 ΒV 509.8 609.2 620.8 603.2 DPS 103.0 130.0 150.0 170.0 Cash Per Share 24.3 112.0 48.6 24.5 **Operating Ratios (%)** 36.0 36.0 36.3 EBITDA Margin 33.5 PBT / Net Sales 33.9 36.7 36.9 37.0 PAT Margin 24.6 27.2 27.3 27.2 Inventory days 87.8 87.0 88.0 88.0 Debtor days 4.5 4.5 5.0 5.0 Creditor days 42.1 44.0 42.0 42.0 **Return Ratios (%)** 38.6 33.2 35.2 39.0 RoE RoCE 44.7 47.4 52.1 52.8 RolC 25.3 26.6 24.9 26.6 Valuation Ratios (x) P/E 19.1 18.6 17.2 16.0 EV / EBITDA 13.9 13.5 12.8 11.8 EV / Net Sales 4.6 4.9 4.6 4.3 Market Cap / Sales 4.7 5.1 4.7 4.3 Price to Book Value 7.4 6.2 6.1 6.2 **Solvency Ratios** Debt/EBITDA 0.0 0.0 0.0 0.0 Debt / Equity 0.0 0.0 0.0 0.0 2.1 **Current Ratio** 1.9 2.0 2.2 Quick Ratio 1.4 1.5 1.7 1.6

FY20

FY21E

FY22E

Source: Company, ICICI Direct Research

Source: Company, ICICI Direct Research

₹ crore

FY23E

| Exhibit 15: ICICI Direct of | cover | age u | nivers | e (FM | CG) | | | | | | | | | | | | | | |
|--------------------------------|--------|--------|--------|---------|-------|---------|-------|---------|-------|-------|-----------------|-------|-------|----------|-------|-------|----------------|-------|-------|
| | CMP | TP | | M Cap | | EPS (₹) | | P/E (x) | | | Price/Sales (x) | | | RoCE (%) | | | RoE (%) | | |
| | (₹) | (₹) | Rating | (₹ Cr) | FY21E | FY22E | FY23E | FY21E | FY22E | FY23E | FY21E | FY22E | FY23E | FY21E | FY22E | FY23E | FY21E | FY22E | FY23E |
| Colgate (COLPAL) | 1,544 | 1,700 | Buy | 38,812 | 33.4 | 35.4 | 37.8 | 46.2 | 43.6 | 40.8 | 8.4 | 7.7 | 7.2 | 83.5 | 100.8 | 123.9 | 64.2 | 78.0 | 96.5 |
| Dabur India (DABIND) | 538 | 595 | Buy | 90,864 | 9.6 | 10.7 | 11.8 | 56.2 | 50.2 | 45.7 | 9.5 | 8.6 | 7.8 | 25.9 | 26.7 | 27.1 | 22.3 | 22.7 | 22.9 |
| Hindustan Unilever (HINLEV) | 2,356 | 2,500 | Buy | 510,548 | 32.4 | 38.8 | 43.2 | 72.7 | 60.7 | 54.5 | 12.0 | 10.4 | 9.7 | 24.5 | 28.5 | 31.2 | 18.6 | 21.9 | 23.9 |
| ITC Limited (ITC) | 218 | 225 | Buy | 213,884 | 11.2 | 12.0 | 13.4 | 19.4 | 18.1 | 16.3 | 4.7 | 4.2 | 3.8 | 27.2 | 30.5 | 35.7 | 20.9 | 23.4 | 27.5 |
| Jyothy Lab (JYOLAB) | 156 | 150 | Hold | 4,957 | 5.8 | 6.1 | 6.7 | 27.1 | 25.6 | 23.2 | 2.7 | 2.5 | 2.3 | 31.1 | 30.9 | 31.5 | 25.7 | 25.1 | 25.6 |
| Marico (MARLIM) | 417 | 440 | Buy | 46,834 | 8.8 | 9.5 | 9.9 | 47.4 | 43.8 | 42.2 | 6.2 | 5.6 | 5.4 | 42.3 | 45.1 | 46.0 | 36.3 | 38.5 | 39.3 |
| Nestle (NESIND) | 17,681 | 18,000 | Hold | 152,970 | 223.4 | 253.4 | 284.2 | 79.1 | 69.8 | 62.2 | 11.5 | 10.4 | 9.5 | 59.9 | 66.6 | 73.7 | 119.1 | 139.2 | 160.6 |
| Tata Consumer Products (TATGLO | 597 | 605 | Buy | 52,158 | 12.0 | 13.5 | 15.1 | 49.7 | 44.1 | 39.4 | 4.8 | 4.4 | 4.1 | 9.8 | 10.5 | 11.1 | 7.8 | 8.6 | 9.3 |
| VST Industries (VSTIND) | 3,762 | 4,200 | Hold | 5,809 | 202.4 | 218.7 | 235.2 | 18.6 | 17.2 | 16.0 | 5.1 | 4.7 | 4.3 | 44.7 | 47.4 | 52.8 | 33.2 | 35.2 | 39.0 |
| Varun Beverage (VARBEV) | 917 | 730 | Hold | 19,429 | 11.3 | 21.7 | 26.6 | 81.1 | 42.2 | 34.5 | 3.0 | 2.5 | 2.3 | 12.3 | 18.6 | 20.7 | 10.1 | 16.7 | 17.6 |
| Zydus Wellness (ZYDWEL) | 1,987 | 2,300 | Buy | 11,359 | 27.8 | 65.7 | 71.7 | 71.5 | 30.2 | 27.7 | 6.1 | 5.4 | 5.0 | 6.9 | 8.3 | 8.9 | 5.9 | 8.6 | 9.2 |

Source: Company, ICICI Direct Research

pankaj.pandey@icicisecurities.com

RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15% Hold: -5% to 15%; Reduce: -15% to -5%; Sell: <-15%



Pankaj Pandey

Head – Research

ICICI Direct Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com

ANALYST CERTIFICATION

I/We, Sanjay Manyal (MBA Finance) Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH00000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavor to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICIC Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.